Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9313874 | 0.88 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL8864270 | 0.87 | L3MBTL1 (0.60) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL147293 | 0.85 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL2089592 | 0.85 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL2954416 | 0.85 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL11782014 | 0.84 | POLB (0.55) | L3MBTL1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL2352584 | 0.83 | MEN1 (0.56) | ALDH1A1HTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL482453 | 0.83 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL1117828 | 0.83 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL1289638 | 0.83 | L3MBTL1 (0.69) | L3MBTL1ALDH1A1HTTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | claimed |
| EP-0070016-A1 | Method and composition for increasing reproduction in mammalian and avian species | THE UNIVERSITY OF UTAH (US) | 1983-01-19 | — | — | EP | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7794761-B2 | Methods for inducing anti-anxiety and calming effects in animals and humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7521468-B2 | Compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1765338-A1 | METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS | Seroctin Research & Technologies, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060223796-A1 | Novel compounds for use in weight loss and appetite suppression in humans | SAVANNA HEALTH LLC | 2006-10-05 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006017281-A1 | METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20050250772-A1 | Methods for inducing anti-anxiety and calming effects in animals and humans | SAVANNA HEALTH LLC | 2005-11-10 | — | — | US | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-20040209877-A1 | Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040192669-A1 | Novel compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999001607-A2 | ENZYMATIC OXIDATION SYSTEM WITH NOVEL ENZYMATIC-EFFECT ENHANCING COMPOUNDS | CALL, KRIMHILD (DE) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | disclosed |
| EP-0070016-A1 | Method and composition for increasing reproduction in mammalian and avian species | THE UNIVERSITY OF UTAH (US) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192669-A1 | Novel compounds for use in weight loss and appetite suppression in humans | CPT1B, FABP4, EGLN1 | L3MBTL1 3060/4885ALDH1A1 1805/4885HTT 1230/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | L3MBTL1 2575/4885ALDH1A1 412/4885HTT 4689/4885 |
| US-20040209877-A1 | Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans | HAAO, HMOX1, IDO1 | L3MBTL1 2652/4885ALDH1A1 659/4885HTT 1548/4885 |
| US-20050250772-A1 | Methods for inducing anti-anxiety and calming effects in animals and humans | CALM1, HAAO, MYB | L3MBTL1 2176/4885ALDH1A1 1338/4885HTT 1003/4885 |
| US-20060223796-A1 | Novel compounds for use in weight loss and appetite suppression in humans | CPT1B, EGLN3, MYB | L3MBTL1 2841/4885ALDH1A1 2194/4885HTT 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.